ABOUT THIS EPISODE
In this interview, discover discuss key findings from the DESTINY-Breast09 trial and their implications for clinical practice, including practical advice for oncologists exploring treatment sequencing strategies with T-DXd.
English
United States
TRANSCRIPT 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
SEARCH PAST EPISODES
Search past episodes of Taylor & Francis.
OTHER EPISODES IN THIS PODCAST
Enzalutamide in biochemically recurrent prostate cancer: design and rationale of the EMBARK study by Taylor & Francis Group
Meet Dakshat Trivedi, your 2026 BRSA finalist.
Disclaimer: The podcast and artwork embedded on this page are from Taylor & Francis Group, which is the property of its owner and not affiliated with or endorsed by Listen Notes, Inc.
EDIT
Thank you for helping to keep the podcast database up to date.
